Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Current Assets (2016 - 2025)

Alterity Therapeutics has reported Current Assets over the past 5 years, most recently at $13.9 million for Q2 2019.

  • For Q2 2019, Current Assets fell 1.49% year-over-year to $13.9 million; the TTM value through Jun 2019 reached $13.9 million, down 1.49%, while the annual FY2019 figure was $13.9 million, 1.49% down from the prior year.
  • Current Assets for Q2 2019 was $13.9 million at Alterity Therapeutics, up from $10105.0 in the prior quarter.
  • Over five years, Current Assets peaked at $27.7 million in Q4 2015 and troughed at $10105.0 in Q4 2018.
  • A 5-year average of $10.6 million and a median of $13.9 million in 2019 define the central range for Current Assets.
  • On a YoY basis, Current Assets climbed as much as 74352.3% in 2018 and fell as far as 99.94% in 2018.
  • Year by year, Current Assets stood at $27.7 million in 2015, then decreased by 17.91% to $22.8 million in 2016, then dropped by 25.96% to $16.8 million in 2017, then tumbled by 99.94% to $10105.0 in 2018, then soared by 137576.92% to $13.9 million in 2019.
  • Business Quant data shows Current Assets for ATHE at $13.9 million in Q2 2019, $10105.0 in Q4 2018, and $14.1 million in Q2 2018.